TrialPath
Recruiting

Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer

NCT07880106 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Exploration of Treatment-Response Biomarkers in Breast Cancer Based on Integrated Liquid-Biopsy Multimodal Omics Features
About this study
Peripheral blood (20 mL) is collected at protocol-defined time points. Serum/Plasma autoantibody repertoires are profiled by PhIP-seq(phage-display immunoprecipitation sequencing); cfDNA methylation is measured by bisulfite-free methylome profiling; exosome RNA is profiled by strand-specific RNA sequencing; and untargeted plasma metabolomics is performed by liquid chromatography-tandem mass spectrometry. The study endpoints include clinical response and pathological complete response after NAC, together with survival follow-up. The study is conducted in accordance with the Declaration of Helsinki and Chinese regulations for investigator-initiated research, and has been approved by the institutional ethics committee. Ambispective - a retrospective pan-cancer cohort (archived samples, 2020 Jan - 2026. Sep) combined with prospective breast cancer cohorts (enrollment 2026. Oct -2029)
Eligibility criteria
Inclusion Criteria: Retrospective pan-cancer cohort: 1. Aged 18 to 80 years; 2. Both genders 3. Clinically and histopathologically confirmed diagnosis of solid malignant tumors, including but not limited to non-small cell lung cancer, colorectal cancer, gastric cancer, hepatocellular carcinoma, or breast cancer. 4. Complete clinical data available, including definitive TNM stage and established treatment plan; 5. Archived peripheral blood samples (serum/plasma) collected during routine clinical care. Prospective neoadjuvant chemotherapy (NAC) breast cancer cohort: 1. Female, aged 18 to 80 years (inclusive); 2. Clinically and pathologically confirmed non-metastatic (M0) breast cancer; 3. Planned standard NAC at the study site, with complete pre-treatment ER, PR, and HER2 immunohistochemistry results available; 4. Voluntary participation with signed written informed consent. Prospective metastatic breast cancer cohort: 1. Female, aged 18 to 80 years (inclusive); 2. Clinically and pathologically confirmed metastatic (M1) breast cancer; 3. Planned standard systemic therapy at the study site, with complete ER, PR, and HER2 immunohistochemistry results available; 4. Voluntary participation with signed written informed consent. Benign/Healthy control group: 1. Healthy female volunteers, or female patients with breast fibroadenoma undergoing minimally invasive biopsy during the same period; 2. Voluntary participation with signed written informed consent. Exclusion Criteria: For prospective breast cancer cohorts: 1. History of mastitis, or systemic rheumatic/autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis); 2. Acute or chronic infectious diseases within the past 6 months (e.g., pneumonia, pulmonary tuberculosis, active hepatitis); 3. Long-term use of glucocorticoids, immunosuppressants, biologic agents, or psychotropic medications (short-term or as-needed use excepted); 4. Inability or refusal to provide informed consent.
Study design
Enrollment target: 2000 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-10-12
Estimated completion: 2034-12-30
Last updated: 2026-11-12
Primary outcomes
  • • Pathological Complete Response (pCR) Rate (At definitive surgery after completion of NAC (approximately 4-6 months after NAC initiation))
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · other
With: Shenshan Medical Center of Sun Yat-sen Memorial Hospital
Contacts & investigators
ContactKai Chen Principal Investigator, MD, PhD · contact · chenkai23@mail.sysu.edu.cn · +86 0660-3863000
All locations (1)
Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen UniversityRecruiting
Shanwei, Guangdong, China
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer · TrialPath